Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial.
Loading...
Embargo End Date
ICR Authors
Authors
Hui, R
Pearson, A
Cortes Castan, J
Campbell, C
Poirot, C
Azim, HA
Fumagalli, D
Lambertini, M
Daly, F
Arahmani, A
Perez-Garcia, J
Aftimos, PG
Bedard, P
Xuereb, L
Loibl, S
Loi, S
Pierrat, M-J
Turner, NC
André, F
Curigliano, G
Pearson, A
Cortes Castan, J
Campbell, C
Poirot, C
Azim, HA
Fumagalli, D
Lambertini, M
Daly, F
Arahmani, A
Perez-Garcia, J
Aftimos, PG
Bedard, P
Xuereb, L
Loibl, S
Loi, S
Pierrat, M-J
Turner, NC
André, F
Curigliano, G
Document Type
Journal Article
Date
2019-12-05
Date Accepted
2019-10-09
Abstract
Citation
Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 29 Suppl 8 pp. viii93 - ?
Source Title
Publisher
Elsevier BV
ISSN
0923-7534
eISSN
1569-8041
Collections
Research Team
Molecular Oncology